作为选择性和可逆性EXosite-ACTive位点 (EXACT) 抑制剂的Aptameric hirudins
Haixiang Yu1, Shekhar Kumar2, James W Frederiksen1
1Department of Surgery, Duke University, Durham, NC, USA.
Nature communications
|May 10, 2024
概括
研究人员开发了新型的EXACT抑制剂,通过结合aptamers和小分子来准血液凝固蛋白酶. 这一策略创造了强效,选择性和可逆的抗凝剂,用于潜在的治疗用途.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 抑制同源凝固蛋白酶,如血栓素和XA因子,对药物开发具有挑战性.
- 吸血生物利用结合的外位素和活性部位结合基因进行蛋白酶抑制.
研究的目的:
- 通过将体和小分子连接起来,设计新的 de novo 抑制剂,称为 EXACT 抑制剂.
- 为研究和治疗应用创造强效,选择性和快速可逆的酶抑制剂.
主要方法:
- 设计的EXACT抑制剂是通过将外位素结合的阿胺与小分子活性位点抑制剂结合在一起.
- 评估了EXACT抑制剂的协同效应,选择性重定向和可逆性.
- 评估了一种化合物HD22-7A-DAB的抗凝活动.
主要成果:
- 胺成分显著增强了小分子抑制剂的功效 (百倍).
- 精确的抑制剂证明了其能够重定向蛋白酶选择性的能力.
- 使用破坏双价结合的抗剂实现了有效的抑制逆转.
- HD22-7A-DAB表现出强烈的抗凝活动,并具有快速发作.
结论:
- 开发的分子工程策略可用于制造选择性,强效和可逆的酶抑制剂.
- 精确抑制剂显示出治疗应用的巨大潜力,特别是在心血管外科手术中.
- 氧核酸合为开发新型酶抑制剂提供了一种多功能方法.
相关概念视频
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
Enzymes
81.5K
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
81.5K
Enzyme Inhibition
78.3K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.3K
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
620
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
620


